Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry†. Issue 3 (23rd February 2019)

• Record Type: Journal Article
• Authors: Obr, Aleš; Prochazka, Vit; Papajik, Tomas; Klener, Pavel; Janikova, Andrea; Salek, David; Belada, David; Pytlík, Robert; Sykorova, Alice; Mocikova, Heidi; Simkovic, Martin; Campr, Vit; Dlouha, Jitka; Furst, Tomas; Trněný, Marek
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 3(2019)
• Page Start: 748
• Page End: 755
• Publication Date: 2019-02-23
• Subjects: Mantle cell lymphoma -- chemotherapy -- maintenance -- rituximab; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1508672
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We analyzed 495 MCL patients from the Czech Lymphoma Study Group data registry. With the median follow-up of 4.4 years, 51.7% patients progressed or relapsed and 34.1% died. Five-year overall survival reached 65.3% and five-year progression free survival 44.1% of the patients. Maintenance rituximab (MR) after first line therapy improved overall and progression free survival compared to the patients under observation only (both p < .001). Elevated beta-2-microglobulin ( p = .003), presence of systemic symptoms ( p = .002), ECOG >0 ( p = .003), age ( p = .014), and MIPI ( p < .001) were associated with MR failure. Patients who did not achieve complete remission have had two-fold higher risk of MR failure ( p < .001). Autologous stem cell transplant reduced the risk of MR failure by 69% ( p < .001). The MIPI and the beta-2-microglobulin were identified as independent predictors of MR failure ( p = .02 and p = .03, respectively). Patients who relapsed/progressed on MR reached shorter OS calculated from the MR start compared to patients without failure (HR = 15.0; p < .001).